Myocardial Infarct

2
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Bristol Myers Squibb
1 program
1
InsulinPhase 41 trial
Active Trials
NCT00237471Terminated40Est. May 2006
Revalesio
RevalesioWA - Tacoma
1 program
1
RNS60Phase 11 trial
Active Trials
NCT01264783CompletedEst. Sep 2011
Zoll
ZollCA - San Jose
1 program
Supersaturated oxygenN/A1 trial
Active Trials
NCT06662890RecruitingEst. Nov 2038

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Bristol Myers SquibbInsulin
RevalesioRNS60
ZollSupersaturated oxygen

Clinical Trials (3)

Total enrollment: 40 patients across 3 trials

NCT00237471Bristol Myers SquibbInsulin

Impact of Tight Glycaemic Control in Acute Myocardial Infarction

Start: Oct 2005Est. completion: May 200640 patients
Phase 4Terminated
NCT01264783RevalesioRNS60

Safety and Tolerability of RNS60 Given by IV to Healthy Subjects

Start: Jul 2011Est. completion: Sep 2011
Phase 1Completed
NCT06662890ZollSupersaturated oxygen

Heart Attack Blood Oxygen Therapy Trial

Start: Oct 2024Est. completion: Nov 2038
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 40 patients
3 companies competing in this space